Intra-Cellular Therapies, Inc. (ITCI)
收市後：
| 前收市價 | 70.34 |
| 開市 | 71.07 |
| 買盤 | 68.74 x 200 |
| 賣出價 | 68.86 x 200 |
| 今日波幅 | 68.48 - 71.35 |
| 52 週波幅 | 45.50 - 84.89 |
| 成交量 | |
| 平均成交量 | 983,360 |
| 市值 | 7.263B |
| Beta 值 (5 年，每月) | 1.01 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.46 |
| 業績公佈日 | 2024年5月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 91.91 |
ZacksAcadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWill Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InvestorPlace3 Biotech Stocks With Skyrocketing Potential: April 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward. The companies in the biotech space are consistently pushing the envelope, making them excellent investment opportunities in a perfect storm situation. One of the biggest catalysts for the biotech sphere is the expected cutback in interest rates later this year. Biotech stocks are considered risky investments, and lower interest
